Arax Advisory Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Arax Advisory Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.87K	Sell	132 -95	-42%	-$2.27K	﹤0.01%	2994
2025 Q4	$6.06K	Sell	227 -19,392	-99%	-$463K	﹤0.01%	2745
2025 Q3	$419K	Buy	+19,619	New	+$464K	0.01%	976
2025 Q2	–	Sell	-174	Closed	-$2.89K	–	3031
2025 Q1	$2.89K	Buy	174 +129	+287%	+$2.34K	﹤0.01%	1964
2024 Q4	$826	Buy	45 +1	+2%	+$16	﹤0.01%	2213
2024 Q3	$677	Hold	44	–	–	﹤0.01%	2350
2024 Q2	$715	Buy	+44	New	+$710	﹤0.01%	2262

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Arax Advisory Partners's ACAD Position: Q1 2026 in Review

Arax Advisory Partners reduced its Acadia Pharmaceuticals (ACAD) stake by 42% in Q1 2026, selling an estimated $2.27K and leaving 132 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Arax Advisory Partners first reported a position in ACAD in Q2 2024 and has held it in 7 quarters since. The position peaked at $419K in Q3 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Arax Advisory Partners held 132 shares of Acadia Pharmaceuticals worth $2.87K as of Q1 2026.
Arax Advisory Partners sold 95 Acadia Pharmaceuticals shares in Q1 2026, an estimated $2.27K.
Acadia Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2994 holding.
Arax Advisory Partners first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
Arax Advisory Partners's Acadia Pharmaceuticals position peaked at $419K in Q3 2025.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.